Fe3O4 Incorporated Metal Organic Framework MIL-100(Fe) As a Drug Carrier

Fe₃O₄ promoted metal organic framework MIL-100(Fe): Can be a promising candidate as a drug carrier

Abhik Bhattacharjee and Sasidhar Gumma

Department of Chemical Engineering, Indian Institute of Technology Guwahati

Email: s.gumma@iitg.ernet.in

In this study, porous metal organic framework (MOF) MIL-100(Fe) and magnetic nanoparticle MOF composites i.e. Fe₃O₄@MIL-100 were investigated as drug delivery vehicles for anticancer drug doxorubicin hydrochloride. Magnetite is an inorganic metal oxide was chosen for its nontoxicity and high magnetic saturation. MIL-100 (Fe) was synthesized by solvothermal route at about 150 °C from its organic linker like trimesic acid (BTC). Magnetite were synthesized according to standard procedures in literature to yield magnetic nanoparticles (MNPs) of about 10-30 nm. A series of MNP and MOF composites i.e. Fe₃O₄@MIL-100(Fe) were prepared by adding magnetite in different molar ratio in the raw precursor of MIL-100 at temperature of 150 °C. All porous adsorbent samples were characterized by X-ray diffraction, Nitrogen adsorption-desorption isotherm and Transmission electron microscopy (TEM) methods. Doxorubicin hydrochloride (DOX), a well-known anticancer drug for the treatment of various cancer syndromes like leukaemia, lymphoma, and carcinoma was chosen as a model drug for current study. The drug was loaded on to the MOF composite by equilibrating the aqueous DOX solution with the porous MNP incorporated MOFs. For release study, “DOX” loaded carriers, were dispersed in simulated phosphate-buffered saline (PBS) solution at a pH of 7.4 and incubated in a shaker at 37 °C in the dark. The sample was centrifuged and the supernatants were collected for analysis at periodic time intervals. A fresh PBS which is equal in volume to that of the sample withdrawn for analysis is added to the contents of the incubation flask. The results indicate that the drug loading capacities of the Fe₃O₄@MIL-100 for the composites studied in this work are higher than both pure Fe₃O₄ and pure MIL-100. The release kinetics also indicate sustained and stable release of “DOX” for more than ten days by incorporating MNPs into MOF structure.

Table 1: Molar compositions and drug loading capacities of different carriers

Drug carriers	Molar ratio Fe:BTC:Fe3O4	“DOX” Loading (wt%)
Fe3O4	0:0:1	11.37
MIL-100	50:33:0	11.09
Fe3O4(50)@MIL-100	50:33:1	18.31
Fe3O4(100)@MIL-100	50:33:2	18.45
Fe3O4(125)@MIL-100	50:33:2.5	19.69
Fe3O4(150)@MIL-100	50:33:3	19.00
Fe3O4(200)@MIL-100	50:33:4	15.14
Fe3O4(400)@MIL-100	50:33:9	13.81

 

 

                          

Fig. 1:  TEM micrograph of Fe₃O₄@MIL-100 and  “DOX” release study on different carriers

References:

1. R. Massart, IEEE Trans.Magn., (1981), 17,1247.

2. P. Horcajada et.al. Nature, (2010), 9, 172.